vaccin
enter
third
centuri
practic
import
medic
intervent
ever
implement
recent
studi
report
far
vaccin
prevent
million
case
diseas
unit
state
everi
year
prevent
million
death
worldwid
equat
prevent
approxim
death
spite
age
approach
vaccin
scienc
current
lead
way
term
introduct
innov
technolog
vaccin
potenti
becom
one
import
tool
maintain
wellb
present
futur
human
gener
timelin
articl
review
histori
vaccin
describ
scientif
discoveri
instrument
develop
novel
safer
vaccin
elimin
infecti
diseas
affect
infant
children
also
provid
perspect
new
technolog
advanc
vaccin
field
articl
aim
provid
exhaust
coverag
vaccin
develop
select
exampl
stori
view
best
illustr
gener
progress
approach
vaccin
design
plagu
athen
human
histori
immun
communic
diseas
achiev
empir
exposur
natur
infect
vaccin
kill
attenu
microorgan
toxin
without
addit
manipul
first
written
record
immun
contagi
diseas
contain
descript
plagu
affect
athen
greec
bce
histori
peloponnesian
thucydid
report
second
year
war
athen
sparta
bce
bce
plagu
spread
athen
kill
onethird
popul
contagion
devast
peopl
longer
care
law
women
liber
tight
custom
popul
lost
faith
religion
thucydid
report
sick
die
individu
found
compass
recov
diseas
knew
experi
person
never
affect
twice
therefor
fear
safeti
although
today
still
debat
whether
plagu
athen
caus
typhoid
fever
epidem
typhu
bubon
plagu
smallpox
anoth
infecti
agent
descript
immun
follow
exposur
diseas
clear
fig
practic
expos
individu
natur
infect
protect
diseas
use
recent
exampl
measl
parti
popular
practic
wherebi
healthi
children
invit
hous
child
diagnos
measl
expos
infect
smallpox
variol
first
report
immun
use
protect
individu
contagi
diseas
come
china
approxim
tenth
pustul
individu
affect
mild
smallpox
dri
blown
nose
uninfect
individu
inocul
scratch
skin
deliber
infect
less
sever
form
diseas
protect
futur
exposur
practic
known
variol
latin
descript
diseas
variu
mean
spot
also
use
africa
becam
increasingli
popular
europ
eighteenth
centuri
time
smallpox
caus
half
million
death
detail
descript
effect
variol
typic
inocul
children
affect
sever
ill
culmin
day
post
exposur
high
fever
senseless
speech
shoot
pain
armpit
usual
week
inocul
inocul
part
cicatr
heal
form
scar
tissu
individu
protect
futur
diseas
howev
sometim
variol
result
death
mani
fear
vaccin
still
inher
individu
today
may
deriv
period
variol
unaccept
sever
side
effect
build
rural
knowledg
contract
cowpox
immun
smallpox
edward
jenner
use
pustul
cow
achiev
result
variol
much
less
sever
side
discoveri
jenner
show
rel
easi
sourc
attenu
pustul
avail
could
protect
devast
diseas
smallpox
consid
offici
birth
vaccin
procedur
name
vaccin
vacca
latin
word
cow
becam
widespread
use
modif
smallpox
fulli
erad
ref
microorgan
vaccin
jenner
awar
microbi
origin
infect
concept
mechan
action
vaccin
scientif
birth
vaccin
came
centuri
later
follow
discoveri
robert
koch
loui
pasteur
infecti
diseas
caus
microorgan
pasteur
start
attenu
microorgan
laboratori
dri
heat
expos
oxygen
passag
differ
anim
host
first
microorgan
attenu
bacterium
caus
chicken
cholera
known
pasteurella
first
human
vaccin
develop
way
contain
rabi
viru
grown
rabbit
spinal
cord
attenu
exposur
dri
air
vaccin
use
success
immun
josef
meister
boy
bitten
rabid
although
primit
rabi
vaccin
sometim
caus
death
immun
individu
procedur
becam
popular
peopl
would
come
pasteur
europ
russia
unit
state
treat
attenu
anthrax
vaccin
produc
time
year
later
follow
discoveri
diphtheria
tetanu
caus
bacteri
toxin
emil
von
behr
shibasaburo
kitasato
found
serum
anim
inocul
toxin
could
protect
human
build
experi
pasteur
albert
calmett
camil
lill
franc
passag
mycobacterium
bovi
strain
time
obtain
attenu
vaccin
bacil
bcg
day
bcg
vaccin
clinic
avail
vaccin
tuberculosi
thu
becam
clear
make
vaccin
necessari
isol
inactiv
inject
microorgan
caus
diseas
toxin
chemic
physic
inactiv
microorgan
wide
use
earli
product
effect
vaccin
typhoid
fever
plagu
cholera
decad
later
pertussi
vaccin
although
effect
longer
use
high
reactogen
advers
effect
includ
fever
pain
swell
inject
site
chemic
inactiv
toxin
describ
gaston
ramon
pari
franc
alexand
glenni
london
uk
discoveri
led
develop
diphtheria
tetanu
toxoid
vaccin
still
use
influenza
vaccin
develop
found
influenza
viru
could
grown
embryon
egg
procedur
still
use
today
manufactur
influenza
vaccin
revolut
vaccin
develop
came
becam
possibl
first
time
grow
virus
cell
cultur
start
grow
wild
polioviru
vitro
new
technolog
enabl
develop
live
polio
vaccin
follow
live
attenu
vaccin
recent
vaccin
varicella
zoster
influenza
vaccin
still
use
today
becam
clear
individu
bactericid
antibodi
specif
meningococc
polysaccharid
protect
meningococc
start
led
develop
purifi
polysaccharid
vaccin
meningococcu
serogroup
c
polysaccharid
vaccin
vaccin
haemophilu
influenza
type
last
vaccin
develop
use
empir
approach
pioneer
jenner
pasteur
wherebi
make
vaccin
necessari
isol
inactiv
inject
microorgan
caus
diseas
compon
diseasecaus
microorgan
start
late
new
technolog
becam
avail
led
vaccin
field
away
empir
approach
enabl
develop
vaccin
would
otherwis
possibl
capsular
polysaccharid
vaccin
introduc
meningococcu
pneumococcu
h
influenza
although
effect
adult
induc
immun
respons
infant
polysaccharid
cellindepend
antigen
stimul
exist
memori
b
cell
pool
preexpos
adult
unabl
induc
b
cell
memori
switch
igm
igg
isotyp
stimul
product
highavid
antibodi
primari
immun
respons
consequ
polysaccharid
immunogen
infant
often
need
vaccin
group
scientist
led
john
robbin
us
nation
institut
health
revisit
paper
publish
oswald
averi
walther
goebel
ref
show
pneumococc
polysaccharid
conjug
protein
abl
induc
antibodi
fig
robbin
colleagu
use
technolog
make
coval
conjug
diphtheria
toxoid
link
capsular
polysaccharid
h
influenza
type
b
describ
first
conjug
conjug
technolog
herald
major
revolut
vaccinolog
within
two
decad
conjug
vaccin
licens
h
influenza
type
b
meningococcu
serogroup
seven
serotyp
case
vaccin
induc
highaffin
antibodi
infant
elimin
diseas
carriag
bacteria
immun
popul
past
decad
technolog
use
develop
vaccin
meningococcu
serogroup
c
six
addit
pneumococcu
serotyp
make
possibl
pneumococc
conjug
clinic
studi
recent
carri
conjug
vaccin
group
b
typhoid
conjug
vaccin
first
exampl
vaccin
could
develop
simpli
grow
microorgan
done
sinc
pasteur
nativ
form
antigen
must
transform
link
carrier
protein
order
make
antigen
immunogen
know
conjug
vaccin
work
naiv
individu
protein
coval
link
polysaccharid
abl
engag
cell
therefor
immun
respons
polysaccharid
becom
cell
depend
two
mechan
propos
explain
conjug
engag
cell
fig
one
model
peptid
deriv
carrier
protein
function
cell
epitop
cell
recogn
protein
model
peptid
function
carrier
anchor
coval
link
sugar
mhc
molecul
recogn
cell
specif
day
still
know
littl
precis
molecular
mechan
antigen
process
natur
cell
help
immunolog
memori
induc
glycoconjug
vaccin
mauric
hilleman
want
make
vaccin
hepat
b
viru
hbv
howev
hbv
could
cultiv
laboratori
therefor
could
use
convent
approach
grow
inactiv
viru
instead
hilleman
develop
vaccin
purifi
inactiv
viruslik
particl
vlp
found
larg
quantiti
plasma
chronic
infect
vaccin
effect
addit
obviou
safeti
risk
major
limit
continu
need
infect
individu
provid
vlp
requir
produc
vaccin
year
recombin
dna
technolog
becam
avail
bill
rutter
pablo
valenzuela
univers
california
berkeley
usa
abl
clone
gene
encod
surfac
antigen
hbv
yeast
system
could
assembl
hbv
antigen
vlp
antigen
ident
purifi
plasma
infect
new
technolog
initi
commerci
merck
made
unlimit
product
vaccin
possibl
simpli
grow
yeast
fermentor
first
time
vaccin
produc
without
cultiv
microorgan
caus
diseas
decad
later
yeast
baculoviru
use
produc
recombin
vlp
virus
grown
laboratori
cultur
includ
human
papilloma
viru
ref
caus
cervic
cancer
vlp
recent
becom
popular
vaccin
research
use
produc
recombin
vaccin
mani
virus
vlp
influenza
viru
respiratori
syncyti
viru
rsv
noroviru
parvoviru
current
test
earlyphas
clinic
addit
product
viral
antigen
could
produc
convent
approach
grow
virus
cultur
recombin
dna
technolog
also
use
field
bacteriolog
remov
toxic
toxin
earli
inactiv
wholecel
pertussi
vaccin
highli
critic
real
purport
side
effect
fever
encephalopathi
research
work
find
vaccin
made
purifi
protein
acellular
vaccin
earli
work
yuji
sato
japan
shown
cultur
supernat
bacterium
contain
two
main
protein
pertussi
toxin
filament
haemagglutinin
ha
sato
made
vaccin
chemic
detoxif
entir
western
world
scientist
develop
vaccin
separ
purifi
toxin
ha
ad
new
antigen
call
pertactin
case
also
vaccin
pertussi
toxin
detoxifi
ad
chemic
use
procedur
describ
ramon
glenni
altern
approach
use
recombin
dna
technolog
detoxif
pertussi
toxin
achiev
clone
sequenc
operon
contain
five
gene
encod
toxin
elimin
toxic
introduc
two
amino
acid
chang
activ
site
mutagen
bacterium
abl
produc
unlimit
quantiti
genet
inactiv
pertussi
toxin
molecul
ongo
clinic
trial
genet
inactiv
toxin
tenfold
immunogen
chemic
detoxifi
toxin
induc
faster
stronger
longerlast
case
recombin
dna
technolog
use
improv
qualiti
safeti
antigen
describ
polysaccharid
conjug
vaccin
success
develop
meningococcu
serogroup
c
w
howev
technolog
could
easili
appli
develop
vaccin
meningococcu
serogroup
b
caus
approxim
meningococcu
case
global
capsular
polysaccharid
serogroup
compos
link
polysial
acid
ident
polysial
acid
present
human
glycoprotein
neural
cell
adhes
molecul
human
immun
system
recogn
meningococc
polysaccharid
self
antigen
therefor
gener
antibodi
respons
research
group
attempt
solv
problem
make
modifi
conjug
polysaccharid
chemic
modifi
introduc
npropionyl
other
use
purifi
howev
none
technolog
result
effect
vaccin
one
approach
partial
success
develop
outermembran
vesicl
omv
obtain
deterg
extract
procedur
elimin
toxic
lipopolysaccharid
bacteri
outer
membran
extract
loos
associ
protein
remov
wellanchor
transmembran
protein
pora
induc
protect
omv
vaccin
success
use
cuba
norway
recent
new
zealand
howev
limit
fact
abl
induc
strainspecif
protect
immun
bacterium
use
make
vaccin
bacteria
express
differ
pora
molecul
studi
center
diseas
control
prevent
cdc
unit
state
indic
least
omv
vaccin
would
requir
make
combin
vaccin
would
effect
meningococcu
serogroup
b
public
first
genom
live
organ
h
influenza
suggest
solut
meningococcu
serogroup
b
vaccin
could
found
sequenc
bacteri
genom
select
new
antigen
discov
convent
technolog
fig
process
genomebas
antigen
discoveri
often
describ
revers
vaccinolog
allianc
vaccin
develop
group
chiron
novarti
group
richard
moxon
expert
meningococc
genet
univers
oxford
uk
laboratori
craig
venter
institut
genom
research
san
diego
usa
start
work
decod
genom
neisseria
meningitidi
serogroup
b
search
novel
comput
analysi
identifi
novel
candid
antigen
clone
express
escherichia
coli
novel
protein
use
immun
mice
sera
test
abil
kill
bacteria
presenc
complement
new
candid
antigen
priorit
investig
basi
bactericid
titr
sequenc
conserv
meningococcu
serogroup
b
strain
level
express
differ
bacteri
isol
absenc
homolog
human
protein
final
three
candid
antigen
select
combin
omv
final
vaccin
formul
first
genomederiv
vaccin
develop
revers
vaccinolog
licens
europ
australia
canada
use
success
unit
state
mass
vaccin
student
univers
princeton
santa
barbara
meningococcu
serogroup
b
outbreak
affect
sever
although
path
licensur
slow
meningococcu
serogroup
b
vaccin
genomebas
antigen
discoveri
appli
one
form
anoth
mani
bacteri
vaccin
includ
antibioticresist
bacteria
staphylococcu
case
genom
aureu
use
rapidli
identifi
antigen
e
coli
express
librari
recogn
serum
antibodi
convalesc
individu
sequenc
one
genom
per
pathogen
becam
possibl
discov
singl
genom
often
suffici
identifi
protect
antigen
speci
therefor
multipl
genom
use
identifi
univers
vaccin
group
b
case
e
coli
genom
pathogen
strain
compar
genom
commens
e
coli
strain
identifi
pathogenspecif
recent
genomebas
screen
also
use
identifi
antigen
chlamydia
mycobacterium
recogn
cell
exampl
genomebas
antigen
discoveri
porphyromona
group
mani
other
everi
case
technolog
deliv
novel
antigen
use
formul
protect
vaccin
revers
vaccinolog
provid
access
entir
antigen
repertoir
bacteria
parasit
power
antigen
discoveri
tool
current
although
avail
genom
sequenc
repres
huge
progress
discoveri
novel
vaccin
antigen
approach
abl
discov
polysaccharid
antigen
solv
problem
face
vaccin
design
context
hiv
rsv
protect
antigen
known
variabl
wrong
conform
research
group
led
craig
venter
success
transplant
synthet
genom
half
million
base
cytoplasm
mycoplasma
event
rais
possibl
use
vitro
synthesi
larg
portion
dna
rna
develop
vaccin
first
vaccin
develop
use
synthet
biolog
test
human
april
chines
cdc
report
discoveri
new
potenti
pandem
avian
influenza
viru
strain
made
sequenc
ha
neuraminidas
na
antigen
viru
avail
onlin
next
day
venter
laboratori
synthes
synthet
dna
encod
ha
na
antigen
strain
use
transfect
cell
togeth
linear
plasmid
encod
six
rna
segment
influenza
viru
day
later
new
viru
gener
synthet
gene
isol
viru
use
seed
manufactur
subunit
vaccin
cell
cultur
subunit
vaccin
test
phase
clinic
studi
shown
induc
protect
level
first
human
trial
vaccin
deriv
use
synthet
biolog
technolog
provid
clear
advantag
acceler
vaccin
avail
case
pandem
fig
parallel
synthet
ha
gene
strain
influenza
viru
use
selfamplifi
mrna
sam
entir
synthet
rna
vaccin
deliv
lipid
nanoparticl
vaccin
readi
anim
immun
day
viru
first
report
mice
develop
protect
titr
haspecif
antibodi
week
second
immun
equat
less
day
first
report
exampl
entir
disrupt
tradit
way
make
influenza
vaccin
usual
influenza
virus
collect
ship
qualifi
centr
cdc
unit
state
nation
biolog
standard
laboratori
unit
kingdom
virus
cocultur
egg
make
reassort
sent
vaccin
manufactur
possibl
use
genom
sequenc
deriv
vaccin
seed
total
synthet
vaccin
pioneer
influenza
viru
could
becom
routin
influenza
viru
also
mani
infecti
agent
think
particularli
use
case
emerg
danger
infecti
agent
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
nearli
two
centuri
jenner
vaccin
innov
driven
discoveri
new
infecti
agent
discoveri
cultiv
order
facilit
largescal
product
kill
live
attenu
vaccin
past
year
seen
develop
technolog
chang
natur
vaccin
enabl
research
design
vaccin
diseas
could
tackl
use
convent
technolog
technolog
revolut
continu
provid
new
method
make
vaccin
antigen
also
new
method
deliv
use
new
formul
new
way
improv
antigen
safeti
novel
adjuv
case
nonliv
vaccin
requir
help
immunostimulatori
molecul
known
adjuv
latin
word
adiuvar
mean
help
first
molecul
use
adjuv
phosphat
hydroxid
salt
aluminium
known
alum
introduc
vaccin
diphtheria
tetanu
toxoid
sinc
success
use
formul
nonliv
vaccin
administ
billion
infant
adult
interestingli
adjuv
human
use
introduc
almost
centuri
mainli
experiment
adjuv
fail
manufactur
stabil
safeti
reason
clinic
trial
oilinwat
emuls
name
novarti
second
adjuv
introduc
human
use
sinc
use
hundr
million
individu
greatli
increas
immunogen
season
influenza
vaccin
particularli
elderli
young
children
necessari
respons
age
group
case
pandem
vaccin
individu
prime
natur
influenza
infect
children
age
month
addit
increas
efficaci
season
trival
influenza
vaccin
emuls
glaxosmithklin
use
pandem
influenza
vaccin
other
stabl
emuls
se
test
preclin
clinic
howev
field
undergon
mark
chang
recent
year
owe
discoveri
signal
pathway
innat
immun
signal
mediat
tolllik
receptor
tlr
thu
first
time
molecular
target
adjuv
reveal
made
possibl
select
natur
agonist
abl
stimul
one
agonist
monophosphoryl
lipid
mpl
target
combin
alum
formul
glaxosmithklin
adjuv
use
one
licens
hpv
tlr
agonist
combin
liposom
formul
malaria
tlr
agonist
cpg
oligonucleotid
agonist
extens
test
clinic
trial
compon
vaccin
formul
direct
variou
target
includ
begin
new
era
adjuv
field
tlr
receptor
nodlik
receptor
use
screen
small
molecul
optim
medicin
chemistri
obtain
synthet
immunodrug
abl
elicit
desir
immun
respons
exampl
small
molecul
target
modifi
attach
linker
phosphat
group
enabl
small
molecul
adsorb
alum
deliv
adjuv
activ
local
antigenpres
cell
lymph
node
contact
vaccin
antigen
therebi
avoid
unnecessari
stimul
tissu
edg
colleagu
unpublish
observ
see
acknowledg
design
total
synthet
smallmolecul
adjuv
emerg
field
expect
develop
near
futur
